DK1265929T3 - Anti-C2/C2a-inhibitorer til komplement aktivering - Google Patents

Anti-C2/C2a-inhibitorer til komplement aktivering

Info

Publication number: DK1265929T3
Authority: DK; Denmark
Prior art keywords: inhibitors; complement activation; antibody; complement; molecules
Prior art date: 2000-03-23

Application number

DK01922629T

Other languages

English (en)

Inventor

Cecily Sun

Michael Fung

William N Sun

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-23

Filing date

2001-03-23

Publication date

2009-11-16

2001-03-23 Application filed by Genentech Inc filed Critical Genentech Inc

2009-11-16 Application granted granted Critical

2009-11-16 Publication of DK1265929T3 publication Critical patent/DK1265929T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Peptides Or Proteins (AREA)

DK01922629T 2000-03-23 2001-03-23 Anti-C2/C2a-inhibitorer til komplement aktivering DK1265929T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19142900P	2000-03-23	2000-03-23
PCT/US2001/009409 WO2001070818A1 (en)	2000-03-23	2001-03-23	Anti-c2/c2a inhibitors of complement activation

Publications (1)

Publication Number	Publication Date
DK1265929T3 true DK1265929T3 (da)	2009-11-16

Family

ID=22705479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01922629T DK1265929T3 (da)	2000-03-23	2001-03-23	Anti-C2/C2a-inhibitorer til komplement aktivering

Country Status (9)

Country	Link
US (4)	US6998468B2 (da)
EP (1)	EP1265929B1 (da)
AT (1)	ATE435873T1 (da)
AU (1)	AU2001249410A1 (da)
DE (1)	DE60139189D1 (da)
DK (1)	DK1265929T3 (da)
ES (1)	ES2329010T3 (da)
PT (1)	PT1265929E (da)
WO (1)	WO2001070818A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1265929T3 (da) *	2000-03-23	2009-11-16	Genentech Inc	Anti-C2/C2a-inhibitorer til komplement aktivering
US8658773B2 (en)	2011-05-02	2014-02-25	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
ES2614274T3 (es) *	2002-09-06	2017-05-30	Alexion Pharmaceuticals, Inc.	Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
US8501705B2 (en) *	2003-09-11	2013-08-06	The Board Of Regents Of The University Of Texas System	Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
ES2551202T5 (es)	2005-11-04	2018-11-30	Genentech, Inc.	Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
WO2007112403A2 (en) *	2006-03-27	2007-10-04	The Regents Of The University Of Colorado	Prevention and treatment of ischemia-reperfusion injury
EP2097455B1 (en) *	2006-11-02	2014-10-22	Genentech, Inc.	Humanized anti-factor d antibodies
EP2979729A3 (en)	2007-02-05	2016-05-11	Apellis Pharmaceuticals, Inc.	Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
WO2010093395A1 (en)	2009-02-13	2010-08-19	Immunomedics, Inc.	Immunoconjugates with an intracellularly-cleavable linkage
CN102482701B (zh)	2009-09-16	2015-05-13	免疫医疗公司	I类抗-cea抗体及其使用
CA2782194C (en)	2009-12-02	2018-01-16	Immunomedics, Inc.	Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
WO2012178083A1 (en)	2011-06-22	2012-12-27	Apellis Pharmaceuticals, Inc.	Methods of treating chronic disorders with complement inhibitors
WO2014028560A2 (en)	2012-08-14	2014-02-20	Ibc Pharmaceuticals, Inc.	T-cell redirecting bispecific antibodies for treatment of disease
CA3124553A1 (en)	2012-10-25	2014-05-01	Bioverativ Usa Inc.	Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da)	2012-11-02	2022-05-16	Bioverativ Usa Inc	Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2017004144A1 (en)	2015-07-01	2017-01-05	Immunomedics, Inc.	Antibody-sn-38 immunoconjugates with a cl2a linker
KR102536723B1 (ko)	2012-12-13	2023-05-30	이뮤노메딕스, 인코오포레이티드	개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
PL3725803T3 (pl)	2013-05-23	2022-04-04	Broteio Pharma B.V.	Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania
BR112016002845A2 (pt)	2013-08-12	2017-09-12	Genentech Inc	composições e métodos para tratar condições associadas ao complemento
WO2015103438A2 (en)	2014-01-02	2015-07-09	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3107577B1 (en)	2014-02-21	2024-03-20	IBC Pharmaceuticals, Inc.	Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en)	2014-02-25	2015-09-22	Immunomedics, Inc.	Humanized anti-CD22 antibody
JP2017515811A (ja)	2014-05-01	2017-06-15	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体変異体及びその使用法
US9580495B2 (en)	2014-06-24	2017-02-28	Immunomedics, Inc.	Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA2961774C (en)	2014-10-07	2023-05-23	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
MX2017006094A (es)	2014-11-10	2017-07-19	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos.
KR20180006379A (ko)	2015-04-06	2018-01-17	바이오버라티브 유에스에이 인코포레이티드	인간화 항-c1s 항체 및 이들의 이용 방법
CA2981543A1 (en)	2015-04-22	2016-10-27	Immunomedics, Inc.	Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
CN107735104B (zh)	2015-06-25	2022-05-03	免疫医疗公司	组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
WO2017075173A2 (en)	2015-10-30	2017-05-04	Genentech, Inc.	Anti-factor d antibodies and conjugates
US10654932B2 (en)	2015-10-30	2020-05-19	Genentech, Inc.	Anti-factor D antibody variant conjugates and uses thereof
AU2017210042B2 (en)	2016-01-20	2021-01-21	396419 B.C. Ltd.	Compositions and methods for inhibiting Factor D
WO2018136827A1 (en)	2017-01-20	2018-07-26	Vitrisa Therapeutics, Inc.	Stem-loop compositions and methods for inhibiting factor d
EP3893924A1 (en)	2018-12-13	2021-10-20	Argenx BVBA	Antibodies to human complement factor c2b and methods of use
EP4013785A4 (en) *	2019-08-12	2023-12-20	CSL Innovation Pty Ltd	COMPLEMENT C2-BINDING PROTEINS AND THEIR USE
US20220356234A1 (en)	2019-10-02	2022-11-10	Alexion Pharmaceuticals, Inc.	Complement inhibitors for treating drug-induced complement-mediated response
IL296256A (en)	2020-03-13	2022-11-01	Genentech Inc	Antibodies against interleukin-33 and uses thereof
EP4150338A1 (en)	2020-05-15	2023-03-22	Alexion Pharmaceuticals, Inc.	Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
JPWO2022239720A1 (da)	2021-05-10	2022-11-17
AU2023210793A1 (en) *	2022-01-29	2024-06-06	Kira Pharmaceuticals (Suzhou) Ltd.	Anti-c2 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5861156A (en) *	1993-01-08	1999-01-19	Creative Biomolecules	Methods of delivering agents to target cells
EP0777474B1 (en)	1994-09-23	2005-12-21	Alexion Pharmaceuticals, Inc.	Methods for the treatment of inflammatory joint disease
DK1265929T3 (da)	2000-03-23	2009-11-16	Genentech Inc	Anti-C2/C2a-inhibitorer til komplement aktivering

2001
- 2001-03-23 DK DK01922629T patent/DK1265929T3/da active
- 2001-03-23 DE DE60139189T patent/DE60139189D1/de not_active Expired - Lifetime
- 2001-03-23 WO PCT/US2001/009409 patent/WO2001070818A1/en active Application Filing
- 2001-03-23 ES ES01922629T patent/ES2329010T3/es not_active Expired - Lifetime
- 2001-03-23 AU AU2001249410A patent/AU2001249410A1/en not_active Abandoned
- 2001-03-23 EP EP01922629A patent/EP1265929B1/en not_active Expired - Lifetime
- 2001-03-23 PT PT01922629T patent/PT1265929E/pt unknown
- 2001-03-23 AT AT01922629T patent/ATE435873T1/de active
- 2001-03-23 US US09/816,839 patent/US6998468B2/en not_active Expired - Lifetime
2005
- 2005-05-24 US US10/908,738 patent/US7927592B2/en not_active Expired - Fee Related
2011
- 2011-03-11 US US13/045,895 patent/US8221756B2/en not_active Expired - Fee Related
2012
- 2012-06-15 US US13/524,465 patent/US8911735B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2001070818A8 (en)	2001-12-06
US7927592B2 (en)	2011-04-19
ES2329010T3 (es)	2009-11-20
AU2001249410A1 (en)	2001-10-03
US8221756B2 (en)	2012-07-17
US8911735B2 (en)	2014-12-16
ATE435873T1 (de)	2009-07-15
US6998468B2 (en)	2006-02-14
PT1265929E (pt)	2009-10-15
WO2001070818A1 (en)	2001-09-27
EP1265929A1 (en)	2002-12-18
US20120251549A1 (en)	2012-10-04
EP1265929B1 (en)	2009-07-08
US20110165169A1 (en)	2011-07-07
US20050196394A1 (en)	2005-09-08
US20010026928A1 (en)	2001-10-04
DE60139189D1 (de)	2009-08-20

Publication	Publication Date	Title
DK1265929T3 (da)	2009-11-16	Anti-C2/C2a-inhibitorer til komplement aktivering
BR9909220A (pt)	2000-11-21	Inibidores de ativação de complemento
HK1225741A1 (zh)	2017-09-15	用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制
KR960704576A (ko)	1996-10-09	CD40에 대한 항체(Antibodies to CD40)
WO2007062245A3 (en)	2007-12-06	Human monoclonal antibody human cd134 (ox40) and methods of making and using same
TW200722518A (en)	2007-06-16	Sc(fv)2 structural isomers
AR085874A2 (es)	2013-10-30	Un anticuerpo monoclonal o un fragmento del mismo que se une a un antigeno
HRP20090527T1 (en)	2009-11-30	Nogo-a neutralising immunoglobulins for treatment of neurological diseases
MA29374B1 (fr)	2008-04-01	Anticorps anti-ccr5 et leurs utilisations
NO20063224L (no)	2006-07-11	Anti-MPL-antistoff
NZ597067A (en)	2012-08-31	Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
NZ611387A (en)	2015-05-29	Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
BRPI0607486A2 (pt)	2009-08-04	anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
WO2007133623A3 (en)	2008-03-13	Peptide diagnostic agent for lyme disease
MX2007000103A (es)	2007-05-11	Bibliotecas de anticuerpos universales.
EA200870072A1 (ru)	2009-04-28	ПРОТИВОВОСПАЛИТЕЛЬНЫЕ dAb
JP2005535562A5 (da)	2006-02-23
WO2002074251A3 (en)	2004-02-19	Monoclonal antibody therapy for pancreas cancer
US9701756B2 (en)	2017-07-11	Humanized antibody or fragment thereof specific for CD45R0
RS52918B (en)	2014-02-28	PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE
RU2009104624A (ru)	2010-09-10	Антитела, модифицирующие раковые заболевания
Maderspach et al.	1991	A Monoclonal Antibody Recognizing K‐but Not γ‐and δ‐Opioid Receptors
IL139571A0 (en)	2002-02-10	A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
BR0307308A (pt)	2004-12-07	Antìgenos de superfìcies larvais nematóides
UA90242C2 (ru)	2010-04-26	МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6